BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 20438541)

  • 1. Intravenous Iron and Maintenance Hemodialysis.
    Agarwal R
    N Engl J Med; 2019 Jun; 380(24):e46. PubMed ID: 31189050
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Iron Deficiency in Heart Failure.
    Shamsi A; Cannata A; Piper S; Bromage DI; McDonagh TA
    Curr Cardiol Rep; 2023 Jul; 25(7):649-661. PubMed ID: 37329419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways.
    Garbowski MW; Bansal S; Porter JB; Mori C; Burckhardt S; Hider RC
    Haematologica; 2021 Nov; 106(11):2885-2896. PubMed ID: 33054113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of redox iron towards an increase in mortality among patients: a systemic review and meta-analysis.
    Sharma S
    Blood Res; 2019 Jun; 54(2):87-101. PubMed ID: 31309086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Labile Side of Iron Supplementation in CKD.
    Slotki I; Cabantchik ZI
    J Am Soc Nephrol; 2015 Nov; 26(11):2612-9. PubMed ID: 25999405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?
    McDonagh T; Macdougall IC
    Eur J Heart Fail; 2015 Mar; 17(3):248-62. PubMed ID: 25639592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing the activity of copper(II) complexes against Leishmania through lipophilicity and pro-oxidant ability.
    Portas Ados S; Miguel DC; Yokoyama-Yasunaka JK; Uliana SR; Espósito BP
    J Biol Inorg Chem; 2012 Jan; 17(1):107-12. PubMed ID: 21866394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Labile iron in cells and body fluids: physiology, pathology, and pharmacology.
    Cabantchik ZI
    Front Pharmacol; 2014; 5():45. PubMed ID: 24659969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron Oxide Nanoparticle Formulations for Supplementation.
    Pai AB
    Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis.
    Rangel EB; Espósito BP; Carneiro FD; Mallet AC; Matos AC; Andreoli MC; Guimarães-Souza NK; Santos BF
    Ther Apher Dial; 2010 Apr; 14(2):186-92. PubMed ID: 20438541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
    Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
    Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited value of zinc protoporphyrin as a marker of iron status in chronic hemodialysis patients.
    Canavese C; Grill A; Decostanzi E; Maddalena E; Barbieri S; Martina G; Fop F; Buglione E; Grechi D; David O; Saitta M; Piccoli G
    Clin Nephrol; 2000 Jan; 53(1):42-7. PubMed ID: 10661481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
    McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
    Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.